AstraZeneca's Datroway wins EU approval in metastatic breast cancer

AstraZeneca has secured European Union approval for Datroway as a first-line treatment for certain adults with unresectable or metastatic triple-negative breast cancer, or TNBC.

The approval covers patients who are not candidates for PD-1 or PD-L1 inhibitor therapy, a form of immunotherapy. That is an important distinction because AstraZeneca says approximately 70% of patients with metastatic TNBC are not candidates for immunotherapy and have historically relied on chemotherapy.

For investors, this is a positive regulatory step backed by strong Phase III results. It gives Datroway a second approved breast cancer indication in the EU and expands the drug's potential role within AstraZeneca's oncology portfolio.

What has been approved?

The European Commission has approved Datroway, also known as datopotamab deruxtecan, as a standalone first-line treatment for eligible adult patients with unresectable or metastatic TNBC.

Triple-negative breast cancer tests negative for three common markers used to classify and treat breast cancer: oestrogen receptors, progesterone receptors and overexpression of HER2. That makes the disease more difficult to target with several established breast cancer treatments.

AstraZeneca describes metastatic TNBC as the most aggressive form of breast cancer. The company estimates that TNBC accounts for approximately 15% of breast cancer cases, with around 81,000 diagnoses in Europe each year.

The approval followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. Full details are available in the original company announcement.

The clinical results supporting approval

The decision was based on the TROPION-Breast02 Phase III trial, which enrolled 644 patients across Africa, Asia, Europe, North America and South America.

The trial compared Datroway against the investigator's choice of chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic TNBC who could not receive immunotherapy.

TROPION-Breast02 measure	Datroway	Chemotherapy
Median overall survival	23.7 months	18.7 months
Median survival improvement	5.0 months	-
Objective response rate	62.5%	29.3%
Reduction in risk of progression or death	43%	-
Patients enrolled	644	644 total across both groups

Overall survival measures how long patients remain alive after entering the trial. Median overall survival reached 23.7 months with Datroway, compared with 18.7 months for chemotherapy, representing a five-month improvement.

Datroway also reduced the risk of disease progression or death by 43% compared with chemotherapy. Its objective response rate, meaning the proportion of patients whose tumours shrank by a predefined amount, was 62.5%, against 29.3% for chemotherapy.

Both overall survival and progression-free survival were dual primary endpoints of the trial. AstraZeneca said the improvements were statistically significant and clinically meaningful.

The safety profile was consistent with previous Datroway breast cancer trials. However, detailed rates for individual adverse events were not disclosed in this announcement.

Why this matters for AstraZeneca investors

There are three main reasons the approval is relevant to the AstraZeneca investment case.

First, Datroway is now approved for two breast cancer indications in the EU. It was already approved for certain patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who had received previous endocrine-based therapy and chemotherapy.

Second, this approval moves Datroway into first-line treatment for an eligible metastatic TNBC population. First-line treatment is the initial therapy given for a disease, so gaining approval at this stage could give the medicine a more central role in patient care than a later-line indication.

Third, the decision is supported by an overall survival benefit rather than only improvements in tumour response or progression-free survival. AstraZeneca and Daiichi Sankyo describe Datroway as the only EU-approved TROP2-directed medicine to demonstrate an overall survival benefit in this first-line setting.

The European Society for Medical Oncology has included Datroway in its clinical guidelines as a Category IA first-line option for metastatic TNBC patients who cannot receive immunotherapy. It is also the preferred option for patients who relapse within six months of completing adjuvant therapy.

What exactly is Datroway?

Datroway is a TROP2-directed antibody drug conjugate, or ADC. An ADC combines an antibody designed to recognise a target on cancer cells with a cancer-killing drug payload.

TROP2 is a protein found across several solid tumours, including TNBC. Datroway is designed to target this protein and deliver its chemotherapy payload more directly to the tumour.

The medicine was discovered by Daiichi Sankyo and is being jointly developed and commercialised with AstraZeneca. Daiichi Sankyo is responsible for manufacturing and supply, while retaining exclusive rights in Japan.

The precise economics of the partnership, including how revenue and profits from this indication will be divided, were not disclosed in the announcement.

The positives and the remaining uncertainties

The strongest positive is the quality of the clinical result. A statistically significant five-month improvement in median overall survival, alongside a 43% reduction in the risk of progression or death, provides a substantial foundation for the European launch.

The approval also strengthens AstraZeneca's broader ADC platform. Datroway is part of a clinical programme containing more than 20 trials across cancers including breast, lung and urothelial cancer.

However, regulatory approval does not automatically translate into rapid commercial success. Launch timing, pricing, reimbursement decisions and physician uptake were not disclosed. These factors will help determine how quickly the approval contributes to sales.

The decision may also have been partly anticipated because Datroway received US approval for the same indication in May 2026, while the European approval followed an earlier positive committee opinion and published trial results.

Investors should therefore separate the clinical and strategic importance of the news from its immediate financial impact, which AstraZeneca has not quantified.

What investors should watch next

Datroway is already approved for this TNBC indication in more than 30 countries and regions. Regulatory reviews are also under way in China and Japan, alongside Australia, Canada, Singapore and Switzerland through Project Orbis.

Further approvals would expand its geographic reach, but the next important evidence will be commercial. Investors should watch for launch details, reimbursement progress, sales disclosures and any updates on adoption in the first-line TNBC setting.

It is also worth viewing the approval alongside AstraZeneca's wider first-half performance and pipeline developments, rather than assessing one regulatory decision in isolation.

A meaningful addition to AstraZeneca's oncology portfolio

This is a clearly positive development for AstraZeneca. Datroway has secured an additional EU indication in a difficult-to-treat cancer, supported by improvements in survival, progression-free survival and tumour response compared with chemotherapy.

The main unanswered question is commercial rather than clinical. AstraZeneca has not disclosed expected sales, pricing, launch timing or the financial contribution from the approval. Even so, the decision broadens Datroway's addressable market and reinforces its position as an important part of AstraZeneca's oncology growth strategy.